Wyeth has signed an agreement with Affymetrix to use its GeneChip microarray technology for three more years, extending the relationship that began in 1994. Under the agreement, Wyeth will continue to apply Affymetrix technology in numerous areas of the drug discovery and development process. Wyeth, one of the first pharma companies to apply genomics in clinical research, will continue to use Affymetrix microarray technology to identify new drug targets in an effort to gain a better underst...